What is the latest market price of Elacetrant in 2025?

Elacestrant is a relatively advanced selective estrogen receptor degrader (SERD) in the world. It is mainly used to treat ER+, HER2- advanced or metastatic breast cancer patients with ESR1 mutations. It is especially suitable for postmenopausal women or individuals who have failed endocrine therapy. Such patients often develop resistance problems after using traditional aromatase inhibitors or fulvestrant and other drugs. However, elastran can bind to and degrade mutated estrogen receptors more effectively, thus reactivating the endocrine treatment pathway. It is one of the key breakthroughs in the field of SERD in recent years.

Currently, elastran has not been officially launched in mainland China, nor has it been included in the national medical insurance directory. Therefore, clinical use mostly relies on overseas drug purchase channels or participation in clinical trials. In the international market, the U.S. FDA has approved the drug for marketing under the trade name Orserdu. The European market has also successively obtained marketing authorization, and has gradually been included in the precision treatment path for breast cancer.

From the market price point of view, the price of the original drug is relatively high in Europe and the United States. According to the public information of overseas patients, the price of each box is about 3 more than 10,000 yuan, which belongs to the category of high-priced targeted drugs. In order to reduce the financial burden, some patients choose to obtain relatively low-priced versions through overseas purchasing channels. For example, the Laos version of generic drugs, the current market price is about RMB 2,000 to 3,000 yuan, and the chemical structure of the generic version is basically the same as that of the original research.

Since generic drugs lack formal registration approval in China, the United States or China, careful consideration still needs to be given to storage, transportation and clinical use safety. For patient groups with financial needs, if the drug has not been approved in China, they can obtain safe and compliant medication channels through relevant institutions. In summary, elastran, as an innovative targeted drug for the treatment of ESR1-mutated breast cancer, has clear molecular mechanisms and clinical value.

Reference materials：https://www.drugs.com/mtm/elacestrant.html